• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

缺氧诱导因子-2α在增生型糖尿病视网膜病变新生血管形成中的作用

The effect of hypoxia-inducible factor-2α expressing in the neovascularization of the proliferative diabetic retinopathy

摘要:

目的:观察HIF-2α在增生型糖尿病视网膜病变(PDR)纤维血管膜中的表达,初步探讨HIF-2α在PDR新生血管形成中的作用。方法:回顾性临床研究。2014年7月至2015年7月于青岛大学附属医院眼科行玻璃体切割手术的PDR患者57例60只眼纳入研究。根据手术前是否行玻璃体腔注射抗VEGF药物治疗将患眼分为PDR未注药组和PDR注药组,分别为30例32只眼、27例28只眼。PDR注药组患眼手术前2~7 d玻璃体腔注射10 mg/ml雷珠单抗0.05 ml(含雷珠单抗0.5 mg )。选取同期特发性黄斑前膜患者18例18只眼作为对照组。于玻璃体切割手术中获得PDR纤维血管膜、黄斑前膜病理标本。免疫组织化学染色法及荧光定量PCR (RT-PCR )检测各组病理标本中HIF-2α、Delta样配体4 (Dll4)、VEGF的表达。多组间相关因子表达差异比较采用Kruskal-Wallis检验。两变量间关系行Spearman相关性分析。结果:免疫组织化学染色结果显示,PDR未注药组、PDR注药组纤维血管膜中HIF-2α、Dll4、VEGF蛋白表达均呈阳性。PDR未注药组HIF-2α、Dll4、VEGF蛋白相对表达量均高于PDR注药组,差异均有统计学意义( t=4.36、6.01、4.82, P=0.000、0.008、0.016)。RT-PCR检测结果显示,PDR未注药组、PDR注药组、对照组纤维血管膜、黄斑前膜中HIF-2α、Dll4、VEGF mRNA相对表达量比较,差异均有统计学意义( H=18.81、19.60、20.50 , P=0.000、0.000、0.000 )。其中,PDR未注药组、PDR注药组HIF-2α、Dll4、VEGF mRNA相对表达量均显著高于对照组;与PDR未注药组比较,PDR注药组HIF-2α、Dll4、VEGF mRNA相对表达量均降低。Spearman相关性分析结果显示,HIF-2α与Dll4、VEGF mRNA相对表达量呈显著正相关( r=0.95、0.87, P<0.05 )。 结论:PDR患眼纤维血管膜中HIF-2α表达高于对照组,且与DLL4、VEGF的表达均呈显著正相关。

更多
abstracts:

Objective:To observe and investigate the effect of HIF-2α in the process of neovascularization of proliferative diabetic retinopathy (PDR).Methods:Retrospective clinical study. From July 2014 to July 2015, 60 eyes of 57 PDR patients diagnosed in Ophthalmology Department of Affiliated Hospital of Qingdao University were included in the study. Twenty-eight eyes of 27 patients received intravitreal injections of 0.5 mg ranibizumab (0.05 ml) at 2-7 days before surgery (ranibizumab group) and other 32 eyes of 30 patients did not (group without ranibizumab). Eighteen eyes of 18 patients with epiretinal membranes were included as controls. Pathological specimens of PDR fibrovascular membrane and premacular membrane were obtained during vitrectomy. The immunohistochemical staining and real-time PCR (RT-PCR) were used to detecting the expression of HIF-2α, Dll4 and VEGF. Kruskal-wallis test was used to compare the expression differences of correlation factors between groups. Spearman correlation analysis was used to analyze the relationship between the two variables.Results:The immunohistochemical staining revealed that there were positive expression of HIF-2α, Dll4 and VEGF in all PDR membranes, regardless of the injection of the ranibizumab. The levels of HIF-2α, Dll4 and VEGF protein in the group without ranibizumab were higher than those of the ranibizumab group ( t=4.36, 6.01, 4.82; P=0.000, 0.008, 0.016). RT-PCR showed that the differences of the mRNA expression of HIF-2α, Dll4 and VEGF were all statistically significant among the PDR patients and controls ( H=18.81,19.60, 20.50; P=0.000, 0.000, 0.000). The expression of HIF-2α, Dll4 and VEGF in the PDR membranes was higher than that of epiretinal membranes from non-diabetic patients. In the PDR patients,the expression of HIF-2α, Dll4 and VEGF of the group without ranibizumab was higher than that of the ranibizumab group. The spearman correlation analysis showed that the expression of mRNA between HIF-2α and Dll4, HIF-2α and VEGF were both significantly correlated ( r=0.95, 0.87; P<0.05). Conclusions:The expression of HIF-2α in the PDR membranes was higher than that of the controls. It is positively correlated with the expression of the DLL4 and VEGF.

More
作者: 郭庆敏 [1] 孟旭霞 [1] 胡迭 [2] 周贤慧 [3] 余川 [4]
作者单位: 青岛大学附属医院眼科 266500(现在河北省眼科医院,邢台 054001) [1] 青岛大学附属医院眼科 266500(现在青岛眼科医院 266071) [2] 青岛大学附属医院眼科 266500(现在烟台业达医院眼科 264006) [3] 青岛大学附属医院眼科 266500(现在武汉艾格眼科医院 430015) [4]
期刊: 《中华眼底病杂志》2020年36卷2期 110-115页 ISTICPKUCSCD
栏目名称: 糖尿病视网膜病变研究
DOI: 10.3760/cma.j.issn.1005-1015.2020.02.005
发布时间: 2024-03-19
  • 浏览:325
  • 下载:213

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷